Aptevo therapeutics inc. (APVO)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Operating Activities
Net income (loss)

2,897

-8,174

-6,924

-13,332

-12,018

-14,128

-12,562

-13,145

-13,854

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-9,945

-14,946

-71,741

-12,839

-12,889

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation

413

269

334

401

594

493

481

449

717

1,055

1,050

1,101

1,678

1,742

1,333

400

334

Depreciation and amortization

455

533

546

573

583

606

597

600

587

136

1,275

875

841

450

1,195

881

836

Gain on sale of Aptevo BioTherapeutics

14,338

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on extinguishment of debt

-2,104

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense and other

137

135

254

112

198

297

213

418

60

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

-

-

-

-

-

-

-

-

-

310

149

-

-

-

-

Income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-15,311

-483

-11

-12

Change in fair value of contingent consideration

-

-

-

-

-

-

-

-

-

-

-

-

-

-183

-280

50

-31

Changes in operating assets and liabilities:
Accounts receivable

-

-896

540

1,577

581

-982

57

3,047

957

1,613

-1,011

1,355

-123

1,325

-5,555

5,056

-2,998

Inventories

-

-1,343

515

2,621

2,561

-2,184

999

1,685

257

-209

-691

125

1,342

-4,935

-8,556

-1,941

1,749

Prepaid expenses and other current assets

1,329

1,074

-2,418

-2,149

-121

-255

210

1,457

-97

813

514

-505

806

1,748

-90

-1,528

3,093

Operating lease right of use asset

243

234

283

217

211

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable, accrued compensation and other liabilities

-3,248

1,100

1,084

-1,614

368

1,711

1,408

1,531

-3,371

-

-

-

-

-

-

-

-

Long-term operating lease liability

228

220

212

236

371

-

-

-

-

-

-

-

-

-

-

-

-

Sales rebates and discounts

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,205

482

-552

278

Accounts payable, accrued compensation and other liabilities

-

-

-

-

-

-

-

-

-

-

-

-223

-4,916

3,634

-957

-1,545

1,347

Changes in assets and liabilities held for sale

-1,719

-

-

-

-

-

-

-

-

-

-

2,408

-2,191

-

-

-

-

Sales and rebates discounts

-

-

-

-

388

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-11,175

-5,100

-7,548

-15,891

-13,844

-7,292

-11,146

-16,006

-16,978

-

-

-

-

-

-

-

-

Investing Activities
Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-29

2

-1,852

-1,575

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-12,027

-6,665

-134

-15,951

-14,112

Proceeds from the maturity of investments

-

-

-

-

-

9,091

28,309

26,914

25,929

17,512

24,029

21,087

8,102

-

-

-

-

Cash received from sale of Aptevo BioTherapeutics

28,120

-

-

-

-

0

0

11

54

-

-

-

-

-

-

-

-

Purchases of property and equipment

-

0

0

0

153

49

360

94

473

297

135

176

794

579

-46

908

1,071

Purchases of investments

-

-

-

-

-

1

0

14,536

1,998

70,342

19,012

141

10,138

-

-

-

-

Net cash (used in) provided by investing activities

28,120

0

4,250

0

-153

9,041

27,949

12,295

23,512

-

-

-

-

-

-

-

-

Financing Activities
Payments of long-term debt, including exit and other fees

22,104

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of tax liability for vested equity awards

-

-

-

-

-

11

-10

65

742

-

-

-

-

-

-

-

-

Proceeds of issuance of common stock, warrants, and pre-funded warrants, net

-

-

24

-113

20,410

-

-

-

-

-

-

-

-

-

-

-

-

Payment of tax liability for vested equity awards

-

-

-

-

-

-

-

-

-

-

32

6

805

-

-

-

-

Proceeds from exercise of common stock options

-

-

-

-

-

-

8

378

186

-

-

-

-

-

-

-

-

Proceeds from issuance of prefunded warrants

-

-

0

0

21

-

-

-

-

-

-

-

-

-

-

-

-

Value of equity awards withheld for tax liability

-

-

-

-

58

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-2,830

4,341

-49,756

-908

-1,071

Transfer from former parent, prior to spin-off

-

-

-

-

-

-

-

-

-

-

-

-

-

26,219

11,427

19,773

13,800

Settlement of contribution receivable from former parent

-

-

-

-

-

-

-

-

-

0

0

0

20,000

-

-

-

-

Net cash provided by (used in) financing activities

-22,104

-135

24

-113

20,373

39

-583

313

-556

-

-

-

-

-

-

-

-

Contingent consideration payments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

91

181

Net cash (used in) provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

19,195

1,106

55,288

19,282

13,619

Increase (decrease) in cash, cash equivalents, and restricted cash

-5,159

-5,235

-3,274

-16,004

6,376

1,788

16,220

-3,398

5,978

-68,735

63,561

8,255

4,338

-

-

-

-

(Decrease) increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,218

5,398

2,423

-1,564